Ep 86: Tudriqev (RP1) FDA Approval
Melanoma Matters

Ep 86: Tudriqev (RP1) FDA Approval

25 أغسطس 202652 دقيقة

In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-V They discuss the FDA Cell and Gene Therapy Advisory Committee's review of the single-arm IGNYTE data and key issues around if this represents a local or systemic therapy, the maths around calculating response rate, and importantly how to identify optimal tumor characteristics for this treatment - what Sapna calls "Larkin-izing" the data. It's a long episode with a short fact check and lots of shoutouts to Kevin Harrington for his work in this space.

تشغيل الحلقة

لا يوجد نص لهذه الحلقة بعد

يمكنك الاستماع إليها في المشغّل. في الحلقات التي لها نص، يمكنك النقر على أي كلمة لترى معناها.